AR128385A1 - Radiofármacos dirigidos al psma e inhibidor de punto de control - Google Patents

Radiofármacos dirigidos al psma e inhibidor de punto de control

Info

Publication number
AR128385A1
AR128385A1 ARP230100214A ARP230100214A AR128385A1 AR 128385 A1 AR128385 A1 AR 128385A1 AR P230100214 A ARP230100214 A AR P230100214A AR P230100214 A ARP230100214 A AR P230100214A AR 128385 A1 AR128385 A1 AR 128385A1
Authority
AR
Argentina
Prior art keywords
mammal
psma
radiopharmaceutical
administering
checkpoint inhibitors
Prior art date
Application number
ARP230100214A
Other languages
English (en)
Inventor
Natalie Grinshtein
Shekoufeh Almasi
Saleemulla Mahammad
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of AR128385A1 publication Critical patent/AR128385A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las terapias de combinación comprenden administrar radiofármacos dirigidos al PSMA y uno o más inhibidores de punto de control. Reivindicación 1: Un método para tratar un mamífero que tiene un tipo de cáncer que expresa el antígeno prostático específico de membrana (PSMA), dicho método comprende: (I) administrar al mamífero un radiofármaco ²²⁵Ac, caracterizado porque el mamífero ha recibido o está recibiendo uno o más inhibidores de puntos de control; (II) administrar al mamífero uno o más inhibidores de puntos de control, en donde el mamífero ha recibido o está recibiendo un radiofármaco ²²⁵Ac; o (III) administrar al mamífero uno o más inhibidores de puntos de control al mismo tiempo en que se administra al mamífero un radiofármaco ²²⁵Ac, en donde en cada aparición, dicho radiofármaco ²²⁵Ac comprende un ²²⁵Ac quelado con un compuesto de la fórmula (1), o un estereoisómero de este.
ARP230100214A 2022-01-28 2023-01-30 Radiofármacos dirigidos al psma e inhibidor de punto de control AR128385A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263304181P 2022-01-28 2022-01-28

Publications (1)

Publication Number Publication Date
AR128385A1 true AR128385A1 (es) 2024-04-24

Family

ID=87469916

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100214A AR128385A1 (es) 2022-01-28 2023-01-30 Radiofármacos dirigidos al psma e inhibidor de punto de control

Country Status (12)

Country Link
US (1) US20250114488A1 (es)
EP (1) EP4469094A1 (es)
JP (1) JP2025504558A (es)
KR (1) KR20240142500A (es)
CN (1) CN118946371A (es)
AR (1) AR128385A1 (es)
AU (1) AU2023210698A1 (es)
CA (1) CA3251186A1 (es)
IL (1) IL314545A (es)
MX (1) MX2024009313A (es)
TW (1) TW202337501A (es)
WO (1) WO2023141719A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325945A (en) * 2023-07-27 2026-03-01 Fusion Pharmaceuticals Inc Radioactive drugs targeting PSMA for cancer treatment
WO2025189134A1 (en) * 2024-03-08 2025-09-12 ARTBIO, Inc. Methods for treating prostate cancer with radiopharmaceuticals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers

Also Published As

Publication number Publication date
IL314545A (en) 2024-09-01
AU2023210698A1 (en) 2024-08-15
TW202337501A (zh) 2023-10-01
US20250114488A1 (en) 2025-04-10
KR20240142500A (ko) 2024-09-30
EP4469094A1 (en) 2024-12-04
CA3251186A1 (en) 2023-08-03
CN118946371A (zh) 2024-11-12
MX2024009313A (es) 2024-08-06
JP2025504558A (ja) 2025-02-12
WO2023141719A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
AR119424A1 (es) Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp
CL2020001133A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664)
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
ECSP22057865A (es) Inhibidores de formas mutantes de egfr
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
MX2022014339A (es) Maquina de terapia de fluido medico que incluye regimen de mantenimiento para la misma.
CO2024000237A2 (es) Inhibidores de cdk2
UY39785A (es) Composiciones para reducir la emisión de metano, métodos para mejorar la eficiencia metabólica de los rumiantes y administración de inhibidores de la metanogénesis
AR019507A1 (es) Uso de los inhibidores de cyp2d6 en terapias de combinacion
MX2021013132A (es) Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
MX2023013410A (es) Terapias de combinacion.
CO2022006965A2 (es) Inhibidores de egfr
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
ES2531084T3 (es) Proceso para la preparación de 2-cianopirrolidinas n-sustituidas
AR124189A1 (es) Compuestos y procedimientos de uso de los mismos
CO2021017202A2 (es) Compuestos tricíclicos
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CO2025015732A2 (es) Inhibidores de cdk2
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
AR086744A1 (es) Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
AR129959A1 (es) Método para tratar enfermedades o trastornos orgánicos con inhibidores de ask1
AR132418A1 (es) Agentes radiofarmacéuticos dirigidos a psma y terapia de combinación con inhibidores de la respuesta al daño de adn